AbbVie's Skyrizi Adds Crohn's Disease Indication In Europe
Skyrizi is the first specific IL-23 inhibitor for the treatment of Crohn's disease in Europe, though the drug was approved with a broader label in the US.
You may also be interested in...
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.